Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863950 · ClinicalTrials.gov registry record · Phase 2
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04863950 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 25 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04863950, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG Imipramine Hydrochloride
Study Locations (1)
Texas
- Mays Cancer Center, UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04863950
The ClinicalTrials.gov registry entry for NCT04863950 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Lomustine is the first listed.
NCT04863950 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04863950 about?
NCT04863950 is a clinical study titled "Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma". This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
What is the current status of trial NCT04863950?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-05-25. Estimated completion is 2026-11.
What conditions does trial NCT04863950 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04863950?
The interventions under investigation include: Lomustine (DRUG), Imipramine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04863950?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04863950 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.